Elan up 9pc on US figures for Tysabri patients
Unison.ie (subscription) - Bray,Ireland
Biogen Idec said that there are now 6600 patients on Tysabri, with a further 3400 awaiting reimbursement approval. This compares with US expectations of ...
See all stories on this topic

Biogen has high hopes for Tysabri's future as earnings soar
Pharma Times (subscription) - London,UK
Global sales of new MS drug Tysabri (natalizumab), which is partnered with Elan and only returned to the market in July after being pulled off on safety ...

Elan Ends Up on Tysabri News
Forbes - NY,USA
American Depositary Shares of Irish biopharmaceutical developer Elan Corp. rose Thursday after Biogen Idec Inc. reported strong sales of Tysabri, ...

Citigroup cautious on Teva 2007 sales
Globes - Rishon Le-Zion,Israel
“Tysabri has been ramping up in the US Market,” Citigroup writes. “In Biogen’s latest results, the company reported that 5000 US patients are currently ...